Back to search results

UWCCC Molecular Tumor Board Registry for Solid and Blood Cancers

This study is observing how well the Precision Medicine Molecular Tumor Board (PMMTB) helps patients with solid tumors or blood cancers. The PMMTB is a group of experts who review your tumor's genetic information to suggest personalized treatment options. Researchers want to see how often doctors accept these recommendations and if patients benefit from the suggested treatments. You may be able to join if you are 18 or older, have a suspected or confirmed cancer, and are undergoing genetic testing of your tumor. The study is currently observing outcomes for up to 5 years.

Study design
This is an observational study, meaning researchers will watch and record outcomes without assigning specific treatments. It aims to include up to 10,000 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will track patient outcomes for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03023202

UWCCC Molecular Tumor Board Registry

Recruiting
Not specifiedAges 18+Observational
University of Wisconsin, Madison
~10,000 participants
Updated 2026-04-13 on ClinicalTrials.gov
What's tested:PMMTB (Precision Medicine Molecular Tumor Board)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Frequency of acceptance of molecular tumor board recommendations
Measured over Up to 5 years
+1 more outcome measured

Conditions

Hematologic Neoplasms
Solid Neoplasm

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT03023202

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsinstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Dustin Deming, MD · PRINCIPAL_INVESTIGATOR · University of Wisconsin, Madison

Who to contact

Cancer Connect
[email protected]
8006228922
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clinically suspected or histologically confirmed solid or hematological malignancy
Undergoing genetic testing of tumor
Ability to understand written informed consent document
Willingness to sign written informed consent document

Exclusion

Pediatric patients (age\<18 years) will be excluded due to a lack of expertise on the molecular tumor committee

What this trial measures

  • Frequency of acceptance of molecular tumor board recommendationsUp to 5 years

    How often the molecular tumor board's recommendations are accepted

  • Benefit from PMMTB recommended treatmentUp to 5 years

    Whether patients benefit from PMMTB recommended treatment